pharmaproff

[pharmaproff]

HPV and HSV Infections – Epidemiology Insights and Forecast 2016-2028 by Pharma Proff

HPV is a group of more than 200 related viruses, which spreads mostly through anal, oral, and vaginal sex. The sexually transmitted HPV infections are categorized into two groups: low-grade, and high-grade HPVs. HPV is generally transmitted through vaginal intercourse, oral and anal sex, and also by intimate skin-to-skin contact. The condoms and dental dams can reduce the likelihood of HPV transmission. Some of the risk factors of this infectious disease are smoking, infectious HPV type, increasing age, immunodeficiency, unprotected sexual intercourse, and presence of other sexually transmitted infections (STIs).

HSV on the other hand is a viral infection which affects the mouth, genitals, or anal area. The virus can spread from one person to another causing outbreaks of sores. HSVs can be categorized into two types: HSV-1 and HSV-2. HSV-1 is majorly transmitted by oral-to-oral contact via sores, saliva, and surfaces in or around the mouth. However, HSV-1 can also be transmitted to the genital area through oral-genital contact, which leads to genital herpes. HSV-2 is mainly transmitted through contact with genital surfaces, skin, sores or fluids of someone infected with the virus.

Browse report overview with detailed TOC on HPV and HSV Infections – Epidemiology Insights and Forecast (2016-2028)

India is projected to have the highest number of incident cases of HPV and prevalent cases HSV infections, amongst the 12MM, followed by China and the U.S., during the period 2016-2028. Moreover, Germany is estimated to have the highest number of incidence cases of HPV infections and prevalent cases of HSV infections, while Spain is anticipated to have the lowest number of cases, amongst the European Union five (EU5) countries (U.K., France, Germany, Italy, and Spain).

[pharmaproff]

Acute Kidney Injury Therapeutics - Clinical Trials, Patents, Designations, and Collaborations

AKI or acute kidney failure is a common medical condition reported among hospitalized patients, especially those with multiple comorbid conditions. AKI can occur due to various reasons including decreased renal perfusion, and obstruction of the urinary collecting system. Dehydration, abdominal pain, rise in blood pressure, mild back pain, and vomiting are some of the symptoms associated with the disease.

AKI is diagnosed through various tests which include measurement of rise in serum creatinine, urinary output and imaging techniques including renal ultrasonography. Consumption of medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs), calcineurin inhibitors, and sulfonamide antibiotics, can result in AKI. Management of AKI requires in-depth understanding of fluid and electrolyte homeostasis, as well as appropriate use of renal replacement therapy (RRT).

The companies who are involved in developing therapeutics for AKI have shown positive clinical results in the various phases of drug development. For instance, AM-Pharma B.V. is developing a recombinant alkaline phosphatase (recAP) enzyme, which is currently in the Phase II stage of development, for the treatment of AKI. In March 2018, AM‐Pharma B.V. announced positive results from Phase II study of recAP in patients with AKI. The STOP-AKI study showed dose-dependent relative reduction in mortality of more than 40% in the treatment group compared to the placebo group.

Browse report overview with detailed TOC on "Acute Kidney Injury (AKI) Therapeutics, 2019 - Pipeline Analysis, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments" at:https://www.pharmaproff.com/report/acute-kidney-injury-therapeutic-pipeline-analysis

[pharmaproff]

Rhinovirus Infection Therapeutics - Pipeline Analysis, Clinical Trials & Results, Patents, Designations

According to a new research report “Rhinovirus Infection Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, rhinovirus infection therapeutics currently exhibits a proliferating pipeline with 10 therapeutic candidates.

Rhinovirus infections, caused by rhinoviruses, occurs in the upper or lower respiratory tracts. The occurrence frequency of the infection is a year-around, but most often in spring and fall seasons. The infections are mostly acknowledged as ‘common cold’, but the infection can also lead to lesser degree pneumonia, sore throats, sinus infections, ear infections, and bronchiolitis. In children, around 8-10 course of occurrence have been observed during the first two-years. The symptoms manifest after the incubation period of viruses (12-24 hours) and last till 7-11 days. The signs and symptoms of the infection include nasal irritation or dryness, headache, less sense of smell and taste, hoarseness, cough, and fever.

According to the research findings, most of the drug candidates are being developed as vaccine and administered by the intramuscular and intranasal route. The major advantage of vaccines includes they generate acquired immunity in the body against the rhinovirus infections. The building immunity by the vaccines resist the complications of infections.

The companies developing therapeutics for the treatment of various infections due to rhinovirus, have shown positive clinical results in the various phases of drug development. For instance, in Pre-Clinical study, TVB-3567, showed positive results and minimized infections caused by rhinovirus, respiratory syntaxial virus, parainfluenza virus, severe adult respiratory syndrome virus, and hepatitis virus. The drug candidate reduced the replication of these viruses and helped in minimizing the number of inflammatory cells in the infected areas of the body. The drug candidate also prevented the emergence of drug resistance.

It has been observed that many pharmaceutical companies are leveraging new and improved technologies for the development of rhinovirus infection therapeutics. These technologies play an important role in the drug development; thereby, helping the companies to develop more specific and effective targeted therapies. For instance, Immune Dampening and Refocusing Technology developed by Biological Mimetics Inc., demonstrated a high potential in designing vaccines by minimizing limitations in the vaccine’s development. The technology focuses on identifying the epitopes that stimulate non-protective, strain-specific, or disease-enhancing immunity. The immune-mapping in technology helps in the identification of structure of antigens. This immune-based technology designed antigens can be introduced into the viral vectors or their recombinants subunits.

Some of the key players involved in the development of rhinovirus infection therapeutics in the late and mid stage include Romark L.C., Johnson & Johnson, Istari Oncology Inc., Merck & Co. Inc., and Vaxart Inc.

Rhinovirus Infection Therapeutics Pipeline Analysis

By Phase By Molecule Type By Route of Administration By Company

The report comprises of detailed pipeline analysis of rhinovirus infection therapeutics, analyzing the emerging therapies and their progress status in different phases of development. Comprehensive insights into the pipeline phase products has been provided with special focus on strategic development activities inclusive of collaboration and licensing information, drug designations, financing, grants, technological advancements, and patent. The report also contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanism of action, and drug origin with relevance to rhinovirus infection therapeutics.

[pharmaproff]

Achondroplasia Therapeutics Pipeline is Witnessing Significant Growth due to Positive Clinical Results

Achondroplasia is a common disorder of dwarfism with disproportionate stature. It is an autosomal dominant disorder that occurs due to mutation in fibroblast growth factor receptor 3 (FGFR3) gene, which is located on short arm of chromosome 4. The disorder is characterized by macrocephaly, shortened-limbs (rhizomelic dwarfism), midface retrusion, and frontal bossing. The achondroplasia therapeutics pipeline study covers seven active drug candidates in different stages of development.

Achondroplasia therapeutics pipeline has majority of candidates in the Pre-Clinical stage of development. A peptide-based drug candidate namely, vosoritide, is in the Phase III stage of development by BioMarin Pharmaceutical Inc., for the treatment of achondroplasia.

The drug candidates developed by several companies for the treatment of achondroplasia have shown positive clinical results in the various phases of drug development. For instance, BioMarin Pharmaceutical Inc.’s drug candidate vosoritide, which is under the Phase III stage of development, has been well-tolerated at all doses in the Phase II stage’s study. The majority of adverse events (AEs) were mild and no serious AEs were reported during the study. Across all doses, injection site reactions and hypotension were the most common drug-related AEs.

Achondroplasia Therapeutics Pipeline Analysis

By Phase

By Molecule Type

By Route of Administration

By Company